Is It Too Late To Consider Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT)?

LeMaitre Vascular, Inc. (NASDAQ:LMAT), might not be a large cap stock, but it received a lot of attention from a substantial price movement on the NASDAQGM over the last few months, increasing to US$67.01 at one point, and dropping to the lows of US$53.45. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether LeMaitre Vascular's current trading price of US$58.01 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at LeMaitre Vascular’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.

Check out our latest analysis for LeMaitre Vascular

What's The Opportunity In LeMaitre Vascular?

According to my valuation model, LeMaitre Vascular seems to be fairly priced at around 8.05% above my intrinsic value, which means if you buy LeMaitre Vascular today, you’d be paying a relatively fair price for it. And if you believe the company’s true value is $53.69, then there isn’t really any room for the share price grow beyond what it’s currently trading. In addition to this, LeMaitre Vascular has a low beta, which suggests its share price is less volatile than the wider market.

What does the future of LeMaitre Vascular look like?

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. LeMaitre Vascular's earnings over the next few years are expected to increase by 43%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value.

What This Means For You

Are you a shareholder? LMAT’s optimistic future growth appears to have been factored into the current share price, with shares trading around its fair value. However, there are also other important factors which we haven’t considered today, such as the financial strength of the company. Have these factors changed since the last time you looked at the stock? Will you have enough confidence to invest in the company should the price drop below its fair value?

Are you a potential investor? If you’ve been keeping an eye on LMAT, now may not be the most advantageous time to buy, given it is trading around its fair value. However, the optimistic prospect is encouraging for the company, which means it’s worth diving deeper into other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.

Diving deeper into the forecasts for LeMaitre Vascular mentioned earlier will help you understand how analysts view the stock going forward. At Simply Wall St, we have the analysts estimates which you can view by clicking here.

If you are no longer interested in LeMaitre Vascular, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.